RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Pranabananda Dutta to Neoplasms

Back to Details
This is a "connection" page, showing publications Pranabananda Dutta has written about Neoplasms.
Pranabananda Dutta
Connection Strength
0.138
Neoplasms
  1. Nava M, Dutta P, Farias-Eisner R, Vadgama JV, Wu Y. Utilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance. Sci Rep. 2019 03 26; 9(1):5141.
    View in: PubMed
    Score: 0.082
  2. Mookerjee A, Mookerjee Basu J, Dutta P, Majumder S, Bhattacharyya S, Biswas J, Pal S, Mukherjee P, Raha S, Baral RN, Das T, Efferth T, Sa G, Roy S, Choudhuri SK. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4339-49.
    View in: PubMed
    Score: 0.034
  3. Loyola AC, Zhang L, Shang R, Dutta P, Li J, Li WX. Identification of methotrexate as a heterochromatin-promoting drug. Sci Rep. 2019 08 12; 9(1):11673.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support